Skip to content

Risk Minimisation Materials

Search for Risk Minimisation Materials...

You can search the eMC for Risk Minimisation Materials (RMMs) by

  • Company
  • Common medicine name
  • Title of Risk Minimisation Material

List all materials for medicines starting with:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Result: Risk Minimisation Materials for medicines starting with the letter D

Certain risk materials on this website are intended for use by healthcare professionals only.

By proceeding you are confirming that you are a healthcare professional.

Want to avoid this message? If you are a Healthcare professional, REGISTER or LOGIN and you will not have to self-certify when you access Risk Minimisation Materials.

Darzalex

Janssen-Cilag Ltd

HCPs-_Important information on safety and risk minimisation of Daratumumab and interference with Blood Compatability Testing

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching

For Healthcare Professionals

Important Information about Blood Transfusions

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

For Healthcare Professionals

DAXAS

AstraZeneca UK Limited

Daxas (roflumilast) Information for Patients

New COPD treatment patient card

Daxas (roflumilast) Information for Prescribers

For Healthcare Professionals

For Healthcare Professionals

Deltyba

Otsuka Novel Products GmbH

Deltyba - Information for patients on use during pregnancy or breastfeeding

An information card is available to aid counselling of women of child-bearing potential before initiating treatment with Deltyba.

For Healthcare Professionals

Deltyba - Risk minimisation information for healthcare providers

Important risk minimisation information for healthcare providers is available and should be read carefully before prescribing, dispensing or administering delamanid. Please ensure that each risk has been carefully considered and the relevant risk minimisation actions taken before initiating treatment.

For Healthcare Professionals

Depakote

SANOFI

Valproate- Checklist HCP – Risks in Female patients

Checklist for prescribers related to Valproate use in female patients.
For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- HCP Booklet – Risks in Female patients

Healthcare professional risk minimisation booklet for Valproate in female patients.
For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- Letter for Pharmacists- HCP- Risks in Female patients

Communication letter to pharmacists explaining risk minimisation materials for managing patients taking Valproate based medicines

For Healthcare Professionals

Valproate- Letter for Prescribers -Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- Letter for Primary Care HCP -Risks in Female patients

Communication letter to HCP's providing primary care, obstetric or family planning services to female patients taking Valproate containing medicines.

For Healthcare Professionals

Valproate- Letter for Specialists – Risks in Female patients

Communication letter explaining risk minimisation materials for specialists managing patients taking Valproate based medicines.
For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- Patient Card – Risks in Female patients

Risk minimization Patient card for Valproate in female patients.
For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

Valproate- Patient Guide – Risks in Female patients

Patient Guide risk minimisation booklet for Valproate in female patients.
For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

Valproate- Poster- Dispensary- Risks in Female patients

FOR DISPENSARY USE ONLY
For hard copies please contact our medical information department at 0845 372 7101 or email
uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- Safety Card- HCP- Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

Valproate- Shelf Barker- HCP- Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

DepoCyte

Napp Pharmaceuticals Limited

Depocyte DHPC

Direct Healthcare Professional Communication (DHCP) letter that contains information on the continuing DepoCyte stock shortage across Europe.

For Healthcare Professionals

Dexamethasone

Aspen

Dianette

Bayer plc

Dianette Patient Card UK

Dianette patient information card.

Dianette Prescriber Checklist UK

Dianette - checklist for prescribers.

For Healthcare Professionals

Disodium pamidronate

medac GmbH

Pamidronate Patient Reminder Cards

This reminder card contains important safety information that you need to be aware of before and during treatment with Pamidronate 3 mg/ml infusions for cancer-related conditions

Wockhardt UK Ltd

Disodium Pamidronate Patient Reminder Card

Advice on the possible side effect osteonecrosis of the jaw (bone damage in the jaw).

Domperidone

Wockhardt UK Ltd

Domperidone (Cardiac Effects) Adverse Drug Reaction Follow Up Form For Healthcare Professionals

Healthcare professionals

As a result of the aforementioned procedure, Marketing Authorisation Holders (MAHs) in the EU for domperidone products have made a commitment to enhanced surveillance, by rigorous follow up of all reports of suspected adverse drug reactions (ADRs) involving domperidone. If you wish to report a suspected ADR concerning any type of cardiac effect, or any other kind of adverse effect, with Wockhardt UK Limited’s Domperidone 10mg Film-Coated Tablets or Domperidone 1mg/ml Oral Suspension, please complete the questionnaire entitled: ‘Domperidone (Cardiac Effects) Adverse Drug Reaction Follow Up Form For Healthcare Professionals' and return to the Drug Safety and Information Department by email (drug.safety@wockhardt.co.uk) or fax (+44 1978 669 430).

For Healthcare Professionals

Domperidone (Heart Associated Effects) Follow Up Form For Non-Healthcare Professionals

Patients

As a result of the aforementioned procedure, Marketing Authorisation Holders (MAHs) in the EU for domperidone products have made a commitment to enhanced surveillance, by rigorous follow up of all reports of suspected adverse drug reactions (ADRs) involving domperidone. Patients must consult their doctor straight away if they suspect they have experienced an ADR whilst taking domperidone. If you wish to report a suspected ADR concerning any type of cardiac effect, or any other kind of adverse effect, with Wockhardt UK Limited’s Domperidone 10mg Film-Coated Tablets or Domperidone 1mg/ml Oral Suspension, please complete the questionnaire entitled: ‘Domperidone (Heart Associated Effects) Follow up Form For Non-Healthcare Professionals' and return to the Drug Safety and Information Department by email (drug.safety@wockhardt.co.uk) or fax (+44 1978 669 430).

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue